

Chapter 164

Systemic Necrotizing Arteritis

Peter A. Merkel & Paul A. Monach

REFERENCES

1. Mahr AD, Neogi T, Merkel PA: Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants. *Clin Exp Rheumatol* **24**(2 Suppl. 41):S82-91, 2006
2. Basu N et al: EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. *Ann Rheum Dis* **69**(10):1744-1750, 2010
3. Watts RA et al: Systemic vasculitis—Is it time to reclassify? *Rheumatology (Oxford)* **50**(4):643-645, 2011; [Epub 2010 Jul 20]
4. Lie JT: Nomenclature and classification of vasculitis: Plus ça change, plus c'est la même chose. *Arthritis Rheum* **37**(2):181-186, 1994
5. Hunder GG et al: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. *Arthritis Rheum* **33**(8):1065-1067, 1990
6. Fries JF et al: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. *Arthritis Rheum* **33**(8):1135-1136, 1990
7. Jennette JC et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* **37**(2):187-192, 1994
8. Ozen S et al: EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. *Ann Rheum Dis* **65**(7):936-41, 2006
9. Merkel PA: Drug-induced vasculitis. *Rheum Dis Clin North Am* **27**(4):849-862, 2001
10. Carlson JA, Ng BT, Chen KR: Cutaneous vasculitis update: Diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. *Am J Dermatopathol* **27**(6):504-528, 2005
11. Carlson JA: The histological assessment of cutaneous vasculitis. *Histopathology* **56**(1):3-23, 2010
12. Carlson JA, Chen KR: Cutaneous vasculitis update: Small vessel neutrophilic vasculitis syndromes. *Am J Dermatopathol* **28**(6):486-506, 2006
13. WGET Research Group: Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial. *Arthritis Rheum* **48**(8):2299-2309, 2003
14. Guillevin L et al: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. *Medicine (Baltimore)* **78**(1):26-37, 1999
15. Guillevin L et al: Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. *Arthritis Rheum* **42**(3):421-430, 1999
16. Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. *Arthritis Rheum* **41**(9):1521-1537, 1998
17. Merkel PA et al: Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. *Ann Intern Med* **126**(11):866-873, 1997
18. Savage J et al: International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). *Am J Clin Pathol* **111**(4):507-513, 1999
19. Choi HK et al: Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: Metaanalysis with a focus on antimyeloperoxidase antibodies. *J Rheumatol* **28**(7):1584-1590, 2001
20. Voskuyl AE et al: Diagnostic strategy for the assessment of rheumatoid vasculitis. *Ann Rheum Dis* **62**(5):407-413, 2003
21. Wooten MD, Jasin HE: Vasculitis and lymphoproliferative diseases. *Semin Arthritis Rheum* **26**(2):564-574, 1996
22. Sene D et al: Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. *J Rheumatol* **31**(11):2199-2206, 2004
23. Rieu V et al: Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. *Rheumatology (Oxford)* **41**(3):290-300, 2002
24. Ramos-Casals M et al: Systemic autoimmune diseases in patients with hepatitis C virus infection: Characterization of 1020 cases (The HISPAMEC Registry). *J Rheumatol* **36**(7):1442-1448, 2009
25. Guillevin L et al: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. *Medicine (Baltimore)* **75**(1):17-28, 1996

26. Trimarchi M et al: Cocaine-induced midline destructive lesions: Clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. *Medicine (Baltimore)* **80**(6):391-404, 2001
27. Trimarchi M et al: Sinonasal osteocartilaginous necrosis in cocaine abusers: Experience in 25 patients. *Am J Rhinol* **17**(1):33-43, 2003
28. Kissin EY, Merkel PA: Diagnostic imaging in Takayasu arteritis. *Curr Opin Rheumatol* **16**(1):31-37, 2004
29. Bakthavachalam S et al: Hearing loss in Wegener's granulomatosis. *Otol Neurotol* **25**(5):833-837, 2004
30. Villiger PM, Guillemin L: Microscopic polyangiitis: Clinical presentation. *Autoimmun Rev* **9**(12):812-819, 2010
31. Savage CO et al: Microscopic polyarteritis: Presentation, pathology and prognosis. *Q J Med* **56**(220):467-483, 1985
32. Niles JL et al: The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. *Arch Intern Med* **156**(4):440-445, 1996
33. Agard C et al: Microscopic polyangiitis and polyarteritis nodosa: How and when do they start? *Arthritis Rheum* **49**(5):709-715, 2003
34. Niiyama S et al: Dermatological manifestations associated with microscopic polyangiitis. *Rheumatol Int* **28**(6):593-595, 2008
35. Hoffman GS et al: Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* **116**(6):488-498, 1992
36. Reinhold-Keller E et al: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. *Arthritis Rheum* **43**(5):1021-1032, 2000
37. Stone JH: Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial. *Arthritis Rheum* **48**(8):2299-2309, 2003
38. Finkielman JD et al: ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. *Am J Med* **120**(7):643 e9-e14, 2007
39. Frances C et al: Wegener's granulomatosis. Dermatological manifestations in 75 cases with clinicopathologic correlation. *Arch Dermatol* **130**(7):861-867, 1994
40. Daoud MS et al: Cutaneous Wegener's granulomatosis: Clinical, histopathologic, and immunopathologic features of thirty patients. *J Am Acad Dermatol* **31**(4):605-612, 1994
41. Barksdale SK et al: Cutaneous pathology in Wegener's granulomatosis. A clinicopathologic study of 75 biopsies in 46 patients. *Am J Surg Pathol* **19**(2):161-172, 1995
42. Hu CH, O'Loughlin S, Winkelmann RK: Cutaneous manifestations of Wegener granulomatosis. *Arch Dermatol* **113**(2):175-182, 1977
43. Sable-Fourtassou R et al: Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. *Ann Intern Med* **143**(9):632-638, 2005
44. Solans R et al: Churg-Strauss syndrome: Outcome and long-term follow-up of 32 patients. *Rheumatology (Oxford)* **40**(7):763-771, 2001
45. Lanham JG et al: Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. *Medicine (Baltimore)* **63**(2):65-81, 1984
46. Calamia KT, Balabanova M: Vasculitis in systemic lupus erythematosus. *Clin Dermatol* **22**(2):148-156, 2004
47. Drenkard C et al: Vasculitis in systemic lupus erythematosus. *Lupus* **6**(3):235-242, 1997
48. Ramos-Casals M et al: Cutaneous vasculitis in primary Sjogren syndrome: Classification and clinical significance of 52 patients. *Medicine (Baltimore)* **83**(2):96-106, 2004
49. Watts RA et al: Rheumatoid vasculitis: Becoming extinct? *Rheumatology (Oxford)* **43**(7):920-923, 2004
50. Bartels C et al: Decline in rheumatoid vasculitis prevalence among US veterans: A retrospective cross-sectional study. *Arthritis Rheum* **60**(9):2553-2557, 2009
51. Frances C et al: Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. *Medicine (Baltimore)* **80**(3):173-179, 2001
52. Solans-Laquer R et al: Paraneoplastic vasculitis in patients with solid tumors: Report of 15 cases. *J Rheumatol* **35**(2):294-304, 2008
53. ten Holder SM, Joy MS, Falk RJ: Cutaneous and systemic manifestations of drug-induced vasculitis. *Ann Pharmacother* **36**(1):130-147, 2002
54. Choi HK et al: Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. *Arthritis Rheum* **43**(2):405-413, 2000
55. Choi HK, Merkel PA, Niles JL: ANCA-positive vasculitis associated with allopurinol therapy. *Clin Exp Rheumatol* **16**(6):743-734, 1998

56. Adu D et al: Polyarteritis and the kidney. *Q J Med* **62**(239):221-237, 1987
57. Guillevin L et al: Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. *Medicine (Baltimore)* **84**(5):313-322, 2005
58. Daoud MS, Hutton KP, Gibson LE: Cutaneous periarteritis nodosa: A clinicopathological study of 79 cases. *Br J Dermatol* **136**(5):706-713, 1997
59. Chen KR: Cutaneous polyarteritis nodosa: A clinical and histopathological study of 20 cases. *J Dermatol* **16**(6):429-442, 1989
60. Moore PM, Cupps TR: Neurological complications of vasculitis. *Ann Neurol* **14**(2):155-167, 1983
61. Calabrese LH, Duna GF, Lie JT: Vasculitis in the central nervous system. *Arthritis Rheum* **40**(7):1189-1201, 1997
62. Tsianakas A et al: Scalp necrosis in giant cell arteritis: Case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. *J Am Acad Dermatol* **61**(4):701-706, 2009
63. Baum EW et al: Giant cell arteritis: A systemic disease with rare cutaneous manifestations. *J Am Acad Dermatol* **6**(6):1081-1088, 1982
64. Kerr GS et al: Takayasu arteritis. *Ann Intern Med* **120**(11):919-929, 1994
65. Vanoli M et al: Takayasu's arteritis: A study of 104 Italian patients. *Arthritis Rheum* **53**(1):100-107, 2005
66. Jain S et al: Current status of Takayasu arteritis in India. *Int J Cardiol* **54** Suppl:S111-S116, 1996
67. Ishikawa K, Maetani S: Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. *Circulation* **90**(4):1855-1860, 1994
68. Lupi-Herrera E et al: Takayasu's arteritis. Clinical study of 107 cases. *Am Heart J* **93**(1):94-103, 1977
69. Maksimowicz-McKinnon K, Clark TM, Hoffman GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. *Arthritis Rheum* **56**(3):1000-1009, 2007
70. Ujiie H et al: Pyoderma gangrenosum associated with Takayasu's arteritis. *Clin Exp Dermatol* **29**(4):357-359, 2004
71. Perniciaro CV, Winkelmann RK, Hunder GG: Cutaneous manifestations of Takayasu's arteritis. A clinicopathologic correlation. *J Am Acad Dermatol* **17**(6):998-1005, 1987
72. Pascual-Lopez M et al: Takayasu's disease with cutaneous involvement. *Dermatology* **208**(1):10-15, 2004
73. Mukhtyar C et al: EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis* **68**(3):310-317, 2009
74. Mukhtyar C et al: EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis* **68**(3):318-323, 2009
75. Fauci AS et al: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. *New Eng J Med* **301**(5):235-238, 1979
76. Jayne D et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* **349**(1):36-44, 2003
77. Gayraud M et al: Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. *Br J Rheumatol* **36**(12):1290-1297, 1997
78. Merkel PA: Part 1: The need for novel treatment regimens for ANCA-associated vasculitis. *Clin Exp Rheumatol* **25**(1 Suppl. 44):S72-S73, 2007
79. De Groot K et al: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* **52**(8):2461-2469, 2005
80. Sneller MC et al: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. *Arthritis Rheum* **38**(5):608-613, 1995
81. Pagnoux C et al: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. *N Engl J Med* **359**(26):2790-2803, 2008
82. Jones RB et al: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* **363**(3):211-220, 2011
83. Stone JH et al: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* **363**(3):221-232, 2010
84. WGET Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med* **352**(4):351-361, 2005
85. Hoffman GS et al: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. *Ann Intern Med* **146**(9):621-630, 2007
86. Jayne DR et al: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* **18**(7):2180-2188, 2007

